Lutetium lu 177 dotatate Intravenous and Sandostatin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Medications like octreotide can reduce the effectiveness of lutetium Lu 177 dotatate depending on when they are administered relative to the dose of lutetium Lu 177 dotatate. In general, long-acting formulations of these medications (usually those given by intramuscular injection) should be discontinued for at least 4 weeks and short-acting formulations should be discontinued for at least 24 hours prior to each dose of lutetium Lu 177 dotatate. You may use octreotide following an infusion of lutetium Lu 177 dotatate, but it is important to adhere to the dosing schedules exactly as prescribed so as to minimize the risk for interaction. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Somatostatin and its analogs may interfere with the therapeutic effects of lutetium Lu 177 dotatate by competitively binding to somatostatin receptors, the site of action for the radiolabeled agent. Lutetium Lu 177 dotatate is internalized upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumor cells, and subsequent beta emission from Lu 177 induces cellular damage by formation of free radicals in both target and neighboring cells.

MANAGEMENT: Long-acting formulations of somatostatin analogs should be discontinued for at least 4 weeks and short-acting formulations for at least 24 hours prior to each dose of lutetium Lu 177 dotatate. During treatment with lutetium Lu 177 dotatate, long-acting octreotide should be administered intramuscularly between 4 to 24 hours after each dose of lutetium Lu 177 dotatate (but not within 4 weeks of each subsequent dose of lutetium Lu 177 dotatate), while short-acting octreotide may be given as needed for symptomatic management (but not within 24 hours before each subsequent dose of lutetium Lu 177 dotatate). Following completion of lutetium Lu 177 dotatate treatment, long-acting octreotide should be continued every 4 weeks until disease progression or up to 18 months following treatment initiation.

Lutetium lu 177 dotatate Intravenous

Generic Name: lutetium lu 177 dotatate

Brand name: Lutathera

Synonyms: Lutetium Lu 177 dotatate, Lutetium Lu 177 Dotatate

What is Lutetium lu 177 dotatate Intravenous?

Sandostatin

Generic Name: octreotide

Brand name: Sandostatin, Sandostatin LAR Depot

Synonyms: n.a.

What is Sandostatin?